摘要
目的探讨抑制AKT通路对埃克替尼耐药的非小细胞肺癌细胞迁移能力的影响。方法采取持续暴露并逐渐增加药物浓度方法筛选建立耐药细胞系,MTT法检测细胞增殖能力,Transwell法检测细胞迁移能力,Western blotting检测蛋白表达。结果耐药细胞PC9/IcoR迁移能力高于PC9细胞(P<0.05);PC9/IcoR细胞表皮生长因子受体及AKT磷酸化水平明显高于PC9细胞(P<0.05);LY294002抑制AKT活化后PC9/IcoR细胞迁移能力明显下降(P<0.05)。结论抑制AKT通路可以抑制埃克替尼耐药的非小细胞肺癌细胞迁移。
Objective To investigate the effect of AKT pathway inhibition on the migration of PC9/IcoR cells.Methods The icotinib resistant cell line was established through continuous exposure of PC9 cells to gradually increasing concentrations of the drug.Cell proliferation,protein expression,and cell migration were analyzed through MTT assay,Western blotting,and Transwell assay,respectively.Results The migration ability of drug-resistant PC9/IcoR cells was higher than that of PC9 cells(P<0.05).The expression levels of the phospho-epidermal growth factor receptor(p-EGFR)and phospho-AKT were higher in PC9/IcoR cells than in PC9 cells(P<0.05).Inhibition of the AKT pathway using LY294002 significantly decreased the migration ability of the PC9/IcoR cells(P<0.05).Conclusion Inhibition of the AKT pathway could inhibit the migration of icotinib-resistant non-small-cell lung cancer cells.
作者
杨旸
王一喆
郑春雷
侯科佐
王晓楠
胡雪君
YANG Yang;WANG Yizhe;ZHENG Chunlei;HOU Kezuo;WANG Xiaonan;HU Xuejun(Department of Respiratory and Infectious Disease of Geriatrics,Institute of Respiratory Disease,The First Hospital,China Medical University,Shenyang 110001,China;Department of Medical Oncology,Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province,The First Hospital,China Medical University,Shenyang 110001,China)
出处
《中国医科大学学报》
CAS
CSCD
北大核心
2019年第6期502-506,共5页
Journal of China Medical University
基金
国家自然科学基金(81472193)
关键词
非小细胞肺癌
埃克替尼耐药
迁移
AKT通路
non-small-cell lung cancer
icotinib-resistance
migration
AKT pathway
